Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Caring for Patients Receiving CAR T-Cell Therapy In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  
Increasing Expertise for Treatment of Non-Hodgkin Lymphoma
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American...
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes With Rahul Banerjee, MD, FACP, and Ajay Major, MD, MBA
Keira Smith
Expert Analysis
Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.  
Selpercatinib Approved for RET Fusion-Positive Non-Small Cell Lung Cancer
Lyn Brook
FDA Updates
The FDA has granted regular approval selpercatinib (Retevmo®, Eli Lilly and Company) for treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) gene fusion non-small cell lung cancer (NSCLC). Selpercatinib previously received an accelerated approval from the FDA based on its initial trial results in May...
Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  
Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  
Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
Keira Smith
Expert Analysis
While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  
Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP
Lyn Brook
Expert Analysis
Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected. In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies. 
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
Knowledge Gained for Treatment of Metastatic Hormone-Sensitive Prostate Cancer
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnose...
Durvalumab Approved for Treatment of Biliary Tract Cancer
Lyn Brook
FDA Updates
The FDA has approved durvalumab (Imfinzi®, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for treatment of locally advanced or metastatic biliary tract cancer. "Biliary tract cancer, a heterogeneous group of malignancies that includes intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater c...
Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer dea...
Staying Up to Date on Endometrial Cancer With Ritu Salani, MD
Lyn Brook
Expert Analysis
Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 2022. In this interview, Ritu Salani, MD, Director of the Division of Gynecologic Oncology at the University of California, Los Angeles (UCLA) Health, touches base on a recent activity she led, Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer. In addition, she discusses updates since recording the activity and why it's important for health care professionals to participate in staying up to date with the evolving landscape of endometrial cancer treatment options.  
Pemigatinib Approved for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Lyn Brook
FDA Updates
The FDA has approved pemigatinib (Pemazyre®, Incyte Corporation) for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with a fibroblast growth factor receptor 1 (FGFR1) rearrangement. This is the first approval and only targeted treatment for MLNs with a FGFR1 rearrangement. "Myeloid/lymphoid neoplasms with a FGFR1 rearrang...
The Future of MRD in Multiple Myeloma Treatment Decision Making With Rahul Banerjee, MD, and Ben Derman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · The Future of MRD in Multiple Myeloma Treatment Decision Making In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
Upgrades in Understanding Therapeutic Strategies for Graft-Versus-Host Disease
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has provided efficiency and knowledge gains encompassing the evolving landscape of therapeutic strategies for graft-versus-host disease (GVHD). Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients a...
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Providing Proficiency for Personalized Care Plans for Metastatic Colorectal Cancer
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has demonstrated knowledge gains pertaining to up-to-date treatment and personalized health care plans for metastatic colorectal cancer (CRC). Recently the American Cancer Society estimated that CRC would see 151,030 new cases, with 52,580 of these diagnoses being fatal, this year alone,...

Copyright © 2022 Oncology Data Advisor. All rights reserved.